Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, ARF can suppress cell migration by antagonizing CtBP2 and the phosphatidylinositol 3-kinase pathway, and these data may explain the increased aggressiveness of ARF-null tumors in mouse models.
|
17909040 |
2007 |
Malignant neoplasm of prostate
|
0.460 |
Biomarker
|
disease |
CTD_human |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
GWASDB |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
GWASCAT |
Multiple loci identified in a genome-wide association study of prostate cancer.
|
18264096 |
2008 |
Malignant neoplasm of endometrium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
Endometrial Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed prostate cancer biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.
|
18264096 |
2008 |
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we show that transcription corepressor CtBP2 directly binds acinus, which is regulated by nerve growth factor (NGF), inhibiting its stimulatory effect on cyclin A1, but not cyclin A2, expression in leukemia.
|
19668232 |
2009 |
Childhood Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we show that transcription corepressor CtBP2 directly binds acinus, which is regulated by nerve growth factor (NGF), inhibiting its stimulatory effect on cyclin A1, but not cyclin A2, expression in leukemia.
|
19668232 |
2009 |
Nasopharyngeal carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CtBP2 proteins are ubiquitously expressed in all lines and tumour samples.
|
20964627 |
2010 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate that CtBP1 and CtBP2 both have p53-dependent and -independent roles in suppressing the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents.
|
20964627 |
2010 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrate that CtBP1 and CtBP2 both have p53-dependent and -independent roles in suppressing the sensitivity of breast cancer cells to mechanistically diverse cancer chemotherapeutic agents.
|
20964627 |
2010 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of CtBP proteins and CTBP1 and CTBP2 mRNA splice forms in breast cancer cell lines and tumour tissue was examined.
|
20964627 |
2010 |
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of CtBP proteins and CTBP1 and CTBP2 mRNA splice forms in breast cancer cell lines and tumour tissue was examined.
|
20964627 |
2010 |
Malignant neoplasm of prostate
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
Prostate carcinoma
|
0.160 |
GeneticVariation
|
disease |
BEFREE |
After allowing for multiple testing, none of the SNPs examined were significantly associated with growth factor or hormone concentrations, and the SNP-prostate cancer associations did not differ by these concentrations, although 4 interactions were marginally significant (MSMB-rs10993994 with androstenedione (uncorrected P = 0.008); CTBP2-rs4962416 with IGFBP-3 (uncorrected P = 0.003); 11q13.2-rs12418451 with IGF-1 (uncorrected P = 0.006); and 11q13.2-rs10896449 with SHBG (uncorrected P = 0.005)).
|
22459122 |
2012 |
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
|
22945647 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
|
22945647 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
C-terminal binding protein-2 (CtBP2), as a transcriptional co-repressor, has been shown to mediate the repression of p16(INK4A) , a tumor suppressor gene product, in primary human cells.
|
23255392 |
2013 |
Squamous cell carcinoma of esophagus
|
0.030 |
Biomarker
|
disease |
BEFREE |
Collectively, all results suggested that CtBP2 might contribute to the progression of ESCC through a negative transcriptional regulation of p16(INK4A).
|
23255392 |
2013 |
Epithelial ovarian cancer
|
0.020 |
Biomarker
|
disease |
BEFREE |
CtBP2 is an ovarian cancer oncogene that may play a significant role in epigenetically silencing BRCA1 function in sporadic epithelial ovarian cancer.
|
23730208 |
2013 |
Carcinoma, Ovarian Epithelial
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We have recently demonstrated that the transcriptional co-repressor C-terminal binding protein 2 (CtBP2) is overexpressed in epithelial ovarian carcinoma.
|
23730208 |
2013 |
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.
|
23730208 |
2013 |
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CtBP2 inhibitor MTOB suppressed ovarian cancer cell survival in a CtBP2-dependent manner.
|
23730208 |
2013 |